We owe a lot to tissue resident memory T cells (T RM). These specialized immune cells are among the body's first responders to disease. Rather than coursing through the bloodstream-as many T cells ...

Cancer-fighting T cells do not simply "run out of energy." They are molecularly reprogrammed. For years, mitochondrial dysfunction has been recognized as a hallmark of exhausted T cells in tumors. Yet ...

Chimeric antigen receptor (CAR) T cell-based therapy has greatly improved cancer treatment, especially for hematologic cancers. 1 By providing T cells with synthetic receptors that target tumor ...

Researchers at the Keck School of Medicine of University of Southern California (USC) have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response ...

The study, published in the journal iScience, found that creatine helps activate a group of immune cells that decide whether ...

The research team engineered CD8+ Jurkat T cells to express SVAR16, a human TCR with intermediate-to-high 2D affinity for the SARS-CoV-2-derived epitope HLAA2:01–YLQ, using lentiviral transduction.

CAR architecture has evolved through four generations. The first relied solely on CD3ζ and lacked potency. Second-generation receptors added either CD28 or 4-1BB costimulation, striking a balance ...

Researchers screening roughly 400 transcription factors found that disabling a single protein, NFIL3, allowed CAR T-cells to sustain their tumor-killing activity longer in preclinical models. The ...

Current therapies for rheumatoid arthritis rely on sustained immunosuppression rather than restoration of immune tolerance, with off-drug remission remaining rare.

Broad-spectrum antibiotic use before and after CAR T correlates with worse overall survival and increased neurotoxicity, although confounding exists because antibiotics cluster with cytokine release ...